π¬ MIPI Calculator (Mantle Cell Lymphoma)
The international prognostic index for MCL.
For informational purposes only, not medical advice. Consult a healthcare professional.
The Mantle Cell Lymphoma International Prognostic Index sorts MCL patients into low, intermediate, and high risk from four routine variables: age, ECOG performance status, LDH relative to normal, and white cell count. Hoster and colleagues derived it in 2008 from over 450 patients. Scores under 5.7 are low risk, 5.7 to 6.2 intermediate, above 6.2 high.
Enter the four values. The calculator returns the MIPI and risk group. A biological variant adds the Ki-67 proliferation index for sharper prediction; this calculator uses the clinical four-variable version.
How to Use This Calculator
Use age at diagnosis, ECOG performance status (0-1 versus 2+), LDH divided by your lab's upper normal limit, and the diagnostic WBC. Enter all four. Read the score and risk group. Your hematologist integrates this with Ki-67, TP53 status, and treatment response.
Enter age, ECOG status, LDH ratio, and WBC.
Read the MIPI score.
Check the risk band: <5.7 low, 5.7-6.2 intermediate, >6.2 high.
Discuss with your hematologist alongside Ki-67 and genetics.
The MIPI Formula
+ 1.367 x log10(LDH/ULN) + 0.9393 x log10(WBC)
The coefficients come from a Cox regression on the derivation cohort: age and performance status capture host reserve, while log-transformed LDH and WBC capture tumor burden and proliferation. Logs matter because the risk impact of WBC going 10 to 100 dwarfs 100 to 110. The cutoffs at 5.7 and 6.2 split the cohort into three equally sized risk groups with clearly separated survival curves. The biological MIPI (MIPI-b) adds Ki-67, the proliferation marker, which independently sharpens prediction and is now standard in trial stratification.
Worked Example
Age 68, ECOG 0-1, LDH 1.2x normal, WBC 12: MIPI is 3.53, in the Low risk (<5.7) band, where original cohorts saw Low ~60%, Int ~35%, High ~20% five-year survival. Raise the WBC to 40 and the score climbs past 6.2 into high risk: leukemic-phase disease behaves worse, which the log-WBC term captures.
Reading the Risk Group
Low risk patients often do well with standard chemoimmunotherapy and may be candidates for less intensive approaches in trials. Intermediate risk is the individualized zone. High risk, especially with TP53 mutation or blastoid morphology, prompts consideration of intensive regimens, BTK inhibitors, CAR-T, or transplant referral. These are group outcomes from the pre-BTK-inhibitor era; modern therapies have improved all three bands, so treat the numbers as context, not prophecy.
Hematology Guides MCL Care
MCL treatment is complex and evolving fast: this score is one input to specialist planning. Do not use it to choose or decline therapy. Ask your hematologist about Ki-67, TP53 testing, and clinical trials, which are central to modern MCL care. For informational purposes only, not medical advice. Consult a healthcare professional.
Related tools: absolute lymphocyte count and NLR ratio.
For informational purposes only, not medical advice. Consult a healthcare professional.
Frequently Asked Questions
What is the MIPI score?
The Mantle Cell Lymphoma International Prognostic Index: a 4-variable score (age, ECOG, LDH ratio, WBC) sorting MCL into low, intermediate, and high risk.
What MIPI is high risk?
Above 6.2. Below 5.7 is low risk; 5.7 to 6.2 is intermediate.
What is the biological MIPI?
MIPI plus the Ki-67 proliferation index, which independently predicts outcome and sharpens risk stratification.
How is MCL treated?
Chemoimmunotherapy backbones plus BTK inhibitors, with transplant or CAR-T for high-risk or relapsed disease. Treatment is highly individualized.
Does TP53 matter more than MIPI?
TP53 mutation marks very high-risk disease regardless of MIPI and changes treatment planning substantially.
What is a good LDH ratio?
At or below 1.0 (normal). Rising LDH reflects tumor burden and turnover.
Can MIPI change over time?
It is calculated at diagnosis. Response to treatment and MRD status take over as the prognostic drivers afterward.
Is mantle cell lymphoma curable?
Generally considered incurable with standard therapy but often controllable for years; newer agents keep extending that horizon.
How does MIPI differ from the newer MIPI-c?
MIPI-c (combined) adds Ki-67, a lab marker of how fast the lymphoma cells divide, to the original four clinical factors. Ki-67 refines the prediction enough that MIPI-c reclassifies about a third of patients into different risk groups. Many centers now report both; MIPI-c is the sharper tool when the biopsy includes Ki-67 staining.
Does a low MIPI mean I can skip aggressive treatment?
Not automatically. MIPI predicts the natural course, but treatment intensity also depends on age, fitness, and how much disease is present. Young, fit patients with low MIPI often still get intensive therapy because they can tolerate it and it offers the best shot at long remission. The score informs the discussion; it does not write the prescription.
What is the blastoid variant, and does MIPI catch it?
Blastoid mantle cell lymphoma is an aggressive form with cells that look immature under the microscope and behave badly regardless of clinical factors. MIPI can underestimate it because the score does not include cell appearance. Pathologists flag the variant explicitly, and oncologists treat it as high risk even when the MIPI says otherwise.